Muscle invasive bladder cancer (MIBC) is a more advanced stage of bladder cancer, where tumours grow into or through the bladder muscle, increasing the risk of spreading beyond the bladder. Understanding the symptoms, diagnosis, and treatment options is crucial for managing the disease effectively.
For a general overview of bladder cancer, including risk factors and early detection, visit our Understanding Bladder Cancer page.
Bladder cancer is most often found in the urothelial or transitional cells that line the inside of the bladder. When tumours grow into or through the muscle wall of the bladder, it is known as muscle invasive bladder cancer (MIBC). When bladder tumours spread into the bladder muscle, they are more likely to spread further and be more life threatening.
The ideal MIBC treatment is to remove the cancer as completely as possible to prevent it from spreading. In most cases, this type of cancer is treated through surgery to remove the bladder completely, called a radical cystectomy, and create a new path for urine to leave the body.
Depending on the health of the patient, chemotherapy is used before surgery, referred to as neoadjuvant chemotherapy, to help remove any cancer cells that may have progressed to outside the bladder. Chemotherapy after surgery is referred to as adjuvant chemotherapy.
Treatment may also be used to avoid surgery to keep the bladder. If you’re older, your urologist may feel that surgery is too risky, you may have other health issues that increase the risk from surgery, or you may have personal reasons for not wanting this major surgery.
There is a risk of recurrence with this type of bladder cancer depending on how quickly the cancer is diagnosed, the extent of the cancer, and the treatment used. There are several treatment options available:
Bladder removal, also known as a radical cystectomy, is a common treatment for MIBC. There are several choices for diverting urine once the bladder is removed:
Bladder Preservation is usually a combination of three treatments for bladder cancer – radiation therapy, chemotherapy and resection of the tumour. The combination of these three treatments is called Tri-modality Therapy (TMT) or Modern Combined-Modality Therapy (CMT).
Muscle invasive bladder cancer patients receive immune checkpoint inhibitors and/or chemotherapy, which in turn activates the body’s immune system. Activated immune cells then attack and destroy cancer cells.
Note: Bacillus Calmette-Guérin (BCG treatment) is an intravesical treatment that’s used to treat non-muscle invasive bladder cancer (NMIBC). It’s not used to treat muscle invasive bladder cancer (MIBC).
Bladder Cancer Canada has produced a helpful Guidebook with information about muscle invasive bladder cancer, how it’s diagnosed and the treatment options available. You can download a free copy of this Guidebook. We have also created a Guidebook focusing on Bladder Preservation which you can download by clicking here.
In addition, we host a moderated public Discussion Forum where you can ask questions, share your experiences and read about the experiences of others.
The Canadian Urological Association establishes guidelines providing evidence-based guidance for healthcare clinicians based on best practices. To review the guidelines regarding muscle invasive bladder cancer, please click here.
We encourage you to contact Bladder Cancer Canada for support if you have muscle invasive bladder cancer by email or by calling 1-866-674-8889.
